Gaucher′s disease

Gaucher′s disease

Gaucher′s disease (GD) is the most common amongst the various disorders classified under the lysosomal storage disorders. GD is a model for applications of molecular medicine to clinical delineation, diagnosis, and treatment. The multiorgan and varied presentation of the disease makes it a challenge...

Full description

Bibliographic Details
Main Authors:	Vijay Bohra, Velu Nair
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2011-01-01
Series:	Indian Journal of Endocrinology and Metabolism
Subjects:	Enzyme replacement therapy Gaucher′s disease glucocerebroside β-glucosidase histiocytes imiglucerase
Online Access:	http://www.ijem.in/article.asp?issn=2230-8210;year=2011;volume=15;issue=3;spage=182;epage=186;aulast=Bohra

Similar Items

Hemorrhagic Aspects of Gaucher Disease
by: Hanna Rsenbaum
Published: (2014-10-01)

The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients
by: Patrick Deegan, et al.
Published: (2021-02-01)

Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease
by: Ari Zimran, et al.
Published: (2018-02-01)

Aspectos clínicos, bioquímicos, moleculares y tratamiento de 2 pacientes con enfermedad de Gaucher Clinical, biochemical and molecular features and the treatment of two patients presenting with Gaucher's disease
by: Kalia Lavaut Sánchez, et al.
Published: (2010-03-01)

Avaliação de dois anos de tratamento da doença de Gaucher tipo 1 com terapia de reposição enzimática em pacientes do estado de São Paulo, Brasil Evaluation of two years of treatment with enzyme replacement therapy in type 1 Gaucher disease patients of São Paulo State, Brazil
by: Elisa A. P. Sobreira, et al.
Published: (2008-01-01)

Gaucher disease in a family from Maranhão
by: Samira Shizuko Parreão Oi, et al.
Published: (2014-10-01)

Newborn screening for Gaucher disease in Japan
by: Takaaki Sawada, et al.
Published: (2022-06-01)

Gaucher Disease: A Case with Unexplained Splenomegaly
by: Ahsan Ahmad Alvi , Ayesha Nayyar , Rabiah Asghar , Muhammad Nadeem Akbar Khan , Ayesha Elahi , Ammar Naqvi
Published: (2018-03-01)

Changing clinical manifestations of Gaucher disease in Taiwan
by: Wen-Li Lu, et al.
Published: (2023-09-01)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
by: Ida Vanessa D. Schwartz, et al.
Published: (2018-03-01)

Early-Onset Colorectal Cancer in a Young Woman with Type 1 Gaucher Disease
by: Nevenka Ridova, et al.
Published: (2022-06-01)

Pediatric Gaucher Disease Presenting with Massive Splenomegaly and Hepatic Gaucheroma
by: Gianluca Bossù, et al.
Published: (2023-05-01)

Pulmonary Involvement Responsive to Enzyme Replacement Therapy in an Elderly Patient with Gaucher Disease
by: Dylan Vellas, et al.
Published: (2021-10-01)

Enzyme replacement therapy in adult patients with type I Gaucher disease
by: R V Ponomarev, et al.
Published: (2019-07-01)

Bilateral femoral osteolytic lesions in a patient with type 3 Gaucher disease
by: Enock Teefe, et al.
Published: (2015-12-01)

Efficacy and Safety of Taliglucerase Alfa for the Treatment of Gaucher Disease: A 9-Year Experience
by: Livia d’Avila Paskulin, et al.
Published: (2022-05-01)

Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease
by: Ying Sun, et al.
Published: (2020-05-01)

Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS)
by: Derralynn A. Hughes, et al.
Published: (2022-08-01)

Study of enzyme replacement therapy for Gaucher Disease: comparative analysis of clinical and laboratory parameters at diagnosis and after two, five and ten years of treatment
by: Ana Maria Almeida Souza, et al.
Published: (2014-10-01)

A 20-Year Longitudinal Study of Plasma Chitotriosidase Activity in Treated Gaucher Disease Type 1 and 3 Patients—A Qualitative and Quantitative Approach
by: Paulina Szymańska-Rożek, et al.
Published: (2023-02-01)

Symmetric, bilateral upper and lower extremity lucent lesions in a patient with Gaucher's disease on enzyme replacement therapy
by: Andrew S. Kuhn, MD, et al.
Published: (2020-11-01)

Diagnosis features of pediatric Gaucher disease patients in the era of enzymatic therapy, a national-base study from the Spanish Registry of Gaucher Disease
by: Marcio Andrade-Campos, et al.
Published: (2017-05-01)

The French Gaucher’s disease registry: clinical characteristics, complications and treatment of 562 patients
by: Stirnemann Jérôme, et al.
Published: (2012-10-01)

Treatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy
by: Christine I. Ha, et al.
Published: (2017-09-01)

In-depth phenotyping for clinical stratification of Gaucher disease
by: Simona D’Amore, et al.
Published: (2021-10-01)

Trends in Glucocerebrosides Research: A Systematic Review
by: Mazarine Desplanque, et al.
Published: (2020-10-01)

Results of a phase I open randomized comparative crossover clinical trial to assess the safety and pharmacokinetics of Glurazyme® (imiglucerase) in comparison with the reference product in healthy volunteers
by: S. B. Fitilev, et al.
Published: (2019-12-01)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
by: Naoto Komada, et al.
Published: (2021-09-01)

Women with Gaucher Disease
by: Maria del Mar Meijon-Ortigueira, et al.
Published: (2024-03-01)

Gaucher's disease in children: Case report from Afghanistan with literature review
by: Turyalai Hakimi, et al.
Published: (2023-09-01)

Gaucher’s Disease – current state of knowledge and future perspectives?
by: Katarzyna Szymańska, et al.
Published: (2024-03-01)

Laboratory diagnosis and follow-up of Romanian Gaucher disease patients
by: Drugan Cristina, et al.
Published: (2017-07-01)

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
by: Yoo-Mi Kim, et al.
Published: (2017-05-01)

Taliglucerase alfa in the longterm treatment of children and adolescents with type 1 Gaucher disease: the Albanian experience
by: Paskal Cullufi, et al.
Published: (2024-02-01)

Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy
by: Paweł Dubiela, et al.
Published: (2023-04-01)

Long-term safety and effectiveness of velaglucerase alfa in Gaucher disease: 6-year interim analysis of a post-marketing surveillance in Japan
by: Rieko Sagara, et al.
Published: (2021-12-01)

Experiencia cubana en la terapia de reemplazo enzimático en la Enfermedad de Gaucher
by: Kalia Lavaut Sánchez, et al.

Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots
by: Claudia Cozma, et al.
Published: (2020-06-01)

Impact of Long-Term Enzyme Replacement Therapy on Glucosylsphingosine (Lyso-Gb1) Values in Patients with Type 1 Gaucher Disease: Statistical Models for Comparing Three Enzymatic Formulations
by: Tama Dinur, et al.
Published: (2021-07-01)

Preparative isolation of cerebrosides (galactosyl and glucosyl ceramide)
by: N S Radin
Published: (1976-05-01)